The global acute myeloid leukemia therapeutics market is anticipated to gain lucrative growth over the forecast period as a consequence of rising incidences of acute myeloid leukemia (AML)and its relapse cases across the globe. The increasing need for advanced therapeutics is also a high-impact rendering driver of this market. Rising incidences of acute myeloid leukemia therapeutics are attributed to factors such as genetic mutations, unhealthy lifestyles, continued exposure to hazardous chemicals such as benzene, and radiation exposure. Moreover, increasing geriatric population base and growing unmet healthcare needs are expected to boost the market growth further. Limitations pertaining to current drug therapies available for acute myeloid leukemia are also expected to induce the need for improved and effective therapies, which will further drive the market. The limitations comprise the inability of these drugs to control relapse cases and adverse side effects including nausea, loss of appetite, and tissue damage. Consequentially, these recent drug therapies include Midostaurin, Cpx-351, Quizartinib, Treosulfan, and Stemex. It is also anticipated to be driven by rising stem cell transplantation procedures, serine-threonine proteins kinases, and presences of various drugs in the pipeline namely, Marqibo, Graspa, Inotuzumab, and Ozogamicin.
The advent of upcoming therapies including farnesyltransferase inhibitors, immunotoxins, alkylating agents, monoclonal antibodies, FMS-like tyrosine kinase 3 inhibitors, and multidrug-resistant modulators are anticipated to upsurge the acute myeloid leukemia (AML)market growth. The benefits of these therapies include long-term survival rates, increased safety, and improved quality. Moreover, higher chances of early identification of leukemia cells, targeted therapy, and reduced chances of relapse of the acute myeloid leukemia are further expected to boost of the forecast period.
The global acute myeloid leukemia therapeutics market is segregated into pipeline drugs, chemotherapy drugs, and chemotherapy regimens. Pipeline drugs include Bosutinib, Vidaza, Vosaroxin, Omapro, Quizartinib, Dacogen, and metabolic inhibitors such as FLT3 inhibitors. Under this segment, FLT3 inhibitors are expected to be the fastest-growing segment of over the next seven years owing to improved targeted therapy in order to treat genetic mutations and improved therapy outlook. Under the chemotherapy drugs segment, there are Cytarabine, Clolar, Gleevac, Sprycel, Fludara, Oncaspar, Nelarabine, and Treanda. Chemotherapy regimens are further segmented into AVD regimen, DC regimen, VCD regimen, FC regimen, Hyper-CVAD regimen, and FCR regimen. As of 2014, AVD regimen dominated the AML market owing to the absence of more effective drug regimens and a lack of novel targeted therapies. Under the chemotherapy drugs segment, there are Cytarabine, Clolar, Gleevac, Sprycel, Fludara, Oncaspar, Nelarabine, and Treanda. Cytarabine held a substantial share in 2014 owing to high survival rates of patients and limited availability of other treatment options. Additionally, benefits such as increased tolerance and ability to be used in combination with other drugs are anticipated to propel the growth of this segment.
Geographically, the acute myeloid leukemia therapeutics market is divided into North America, Europe, Asia Pacific, Latin America, and MEA. As of 2014, North America held a substantial share of the market owing to prominent growth factors including rising incidences of acute myeloid leukemia and increasing geriatric population. Furthermore, advanced healthcare infrastructure, rising need for targeted therapies, huge investment in the development of pipeline drugs, and awareness amongst the population base induced market growth in this region. Asia Pacific is expected to be the fastest-growing region over the forecast period owing to growth factors such as rising investments, rising disposable incomes, increasing cancer awareness, and improving healthcare infrastructure. Additionally, increasing inclination towards therapies such as targeted therapies resulting in low collateral damage and stronger efficacy is also anticipated to propel the demand for the market in this region.
The key market companies include Ambit Biosciences Corporation, Genzyme Corporation Celgene Corporation, Clavis Pharma ASA, Sunesis Pharmaceuticals Inc., Cephalon Inc., Bristol-Myers Squibb, Novartis International AG, and GlaxoSmithKline. These companies focus on new drug pipelines, agreements, and collaboration. These players also focus on extensive clinical trials, high R&D investment, and geographic targeting in order to capture larger market share. These companies also aim at improving the overall quality and providing improved patient care in order to capitalize their market shares.
This report has a service guarantee. We stand by our report quality.
We are in compliance with GDPR & CCPR norms. All interactions are confidential.
Design an exclusive study to serve your research needs.
Get your queries resolved from an industry expert.
"The quality of research they have done for us has been excellent..."
Multiple therapeutic regimens are being followed across the globe in attempts to come up with a reliable treatment for Covid-19. One line of treatment includes the use of hydroxychloroquine, while a second treatment line focuses to use antiviral drugs used in the disease management of HIV. Both these approaches have surged demand from advanced antivirals and antimalarial drugs. This impacts the drug manufacturers as an off label indication for these drug classes has to be worked upon. At the moment, the WHO has not prescribed any of these approaches, neither they have commented if one is better than the other. The report will account for Covid19 as a key market contributor.